First of all, to our knowledge, it is the first comparative comprehensive pharmacoeconomic evaluation for the three CDK4/6 inhibitors and letrozole monotherapy in the first-line use of HR+/HER2- advanced breast cancer. The gene discussed is CDK4; the disease is breast cancer.